Tumour necrosis factor (TNF) is an important inflammatory disease mediator in a wide spectrum of articular diseases, including adult and juvenile rheumatoid arthritis (RA, JRA). Etanercept (Enbrel), approved in the United States and in Europe for use in patients with RA and JRA, is an eVective inhibitor of TNF that has been shown to provide rapid and sustained improvement in both of these diseases. Long term studies continue to show that etanercept controls signs and symptoms of RA and JRA with no change in rate or type of adverse event over time. To demonstrate that etanercept is eVective as first line treatment for patients with early active RA who have not been previously treated with methotrexate, and to examine the eVect of etanercept on radiographic progression, a double blind, placebo controlled study was recently conducted, comparing etanercept with methotrexate (median dose 20 mg per week). Both etanercept 25 mg twice weekly and rapidly escalated methotrexate were eVective in reducing the signs and symptoms of RA, and etanercept was significantly better than methotrexate in slowing the rate of radiographic erosions. In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also eVective in reducing disease activity in PsA. Etanercept has been well tolerated in all of these clinical trials and oVers an important new treatment option to patients with inflammatory articular diseases. (Ann Rheum Dis 2000;59(suppl I):i46-i49) 
Tumour necrosis factor and etanercept
The role of tumour necrosis factor (TNF) in rheumatoid arthritis (RA) and other rheumatological diseases has been previously described. 1 Produced by synoviocytes and macrophages, TNF activates the endothelium, stimulates fibroblast proliferation, induces matrix metalloproteinase production, stimulates production of interleukin 1 (IL1) and interleukin 6, and activates osteoclasts via IL1 stimulation. [2] [3] [4] [5] [6] [7] Recombinant human soluble TNF receptor (etanercept) is a dimeric fusion protein consisting of the extracellular portion of the human p75 TNFR linked to the Fc portion of a type 1 human immunoglobulin (IgG1). 8 The primary action of etanercept is to bind and inactivate soluble and cell bound TNF and lymphotoxin . Although the Fc region contains the complement binding domain, etanercept does not fix complement or lyse TNF expressing cells in vitro. 9 In addition, the presence of the Fc portion of human IgG1 in etanercept results in a relatively long median half life of 4.8 days and a high binding aYnity (K i = 10 −10 M). 8 Etanercept is eVective in suppressing inflammation in animal models of arthritis.
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Etanercept clinical trials
Positive results from phase I and II trials led to further evaluation of etanercept in patients with active RA whose disease was not controlled by disease modifying antirheumatic drugs (DMARDs). 11 12 Phase III studies have confirmed that patients show rapid and sustained improvement in adult and juvenile RA (JRA) disease activity and functional status during etanercept treatment. [13] [14] [15] Etanercept has been approved in the United States and Europe for use alone or in combination with methotrexate in patients with RA and JRA who have failed treatment with at least one other DMARD. Etanercept was recently approved in the United States for use as first line treatment for reduction of signs and symptoms of disease and prevention of structural damage in patients with RA.
LONG TERM ETANERCEPT IN DMARD REFRACTORY
RA PATIENTS
Patients from clinical trials of DMARD refractory RA (n = 713) were eligible to continue with etanercept treatment and have been followed up for up to 41 months (1152 patient years). 16 Data from these patients show that etanercept has been well tolerated. There was no change in rate or type of any adverse event with prolonged use of etanercept, and the rate of infections associated with hospitalisation and/or use of intravenous antibiotics did not increase over time. No instances of opportunistic infection or tuberculosis have been seen. In all clinical trials of etanercept in DMARD refractory RA, the number of reported cases of cancer has been similar to the expected rate in the general age and sex matched population calculated from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. 17 There has been no predominant cancer type. Overall, the types and rates of adverse events seen in open label extensions were similar to those seen in controlled studies of etanercept. Of the patients treated with 24 months of continuous etanercept treatment, 76% achieved at least an ACR20 response, 44% an ACR50, and 26% an ACR70. Of the 388 patients who were receiving baseline corticosteroid treatment in these studies, 17% were able to discontinue corticosteroid use, 54% were able to decrease their doses, and only 7% required a dose increase. 16 
ETANERCEPT IN METHOTREXATE NAIVE RA
PATIENTS
With demonstrated evidence that etanercept controls the signs and symptoms in patients with longstanding RA, a study was initiated to determine the ability of etanercept to improve signs and symptoms and to slow radiographic progression in RA patients who had not been treated previously with methotrexate. 18 19 This multicentre, randomised, double blind study compared improvement in signs and symptoms and radiographic progression in RA patients treated with etanercept with those treated with high dose oral methotrexate, which has been considered to be the most eVective single agent DMARD available to treat RA. The trial was conducted in 632 patients who had active RA of three years or less duration, who had never been treated with methotrexate, and who had risk factors for rapidly progressive joint damage (that is, were rheumatoid factor positive or had erosions on baseline radiographs). Patients received either 25 mg or 10 mg of etanercept subcutaneously twice a week or methotrexate, rapidly dose escalated from 7.5 mg to 20 mg orally per week over an eight week period. End points included the ability of etanercept, compared with methotrexate, to reduce the rate of joint damage over 12 months and to reduce the signs and symptoms of RA over six months.
Although mean duration of disease of patients at study entry was less than one year, patients had very active disease, with baseline means of 24 swollen joints and 31 tender joints and a baseline mean Health Assessment Questionnaire (HAQ) score of 1.4. Eighty eight per cent of patients were positive for rheumatoid factor. The mean disease activity score (DAS) for all patients in the trial was 5.2, with 90% having high disease activity (DAS > 3.7) at baseline. 20 21 Results of the trial showed that etanercept slowed disease progression and improved signs and symptoms of disease activity. As in previous trials, the etanercept 25 mg twice weekly dose was found to be more eVective than the etanercept 10 mg twice weekly dose. More patients in the etanercept 25 mg group than in the MTX group completed one year of study drug compared with methotrexate (85% versus 79%, respectively).
Improvement in the etanercept 25 mg group was seen early in the study, as shown by improvement in the DAS (fig 1) . At one month, the mean DAS fell to 3.9 for the etanercept 25 mg group, compared with 4.6 for the methotrexate group (p < 0.001). At two months, the mean DAS was 3.6 for the etanercept 25 group compared with 4.1 for the methotrexate group (p = 0.026). At six months, the mean DAS for the etanercept 25 mg group was 3.2 compared with 3.1 for the methotrexate group (p = NS).
Response as measured by the European League Against Rheumatism (EULAR) criteria was also seen early in the study. 21 At one month, 15% of the etanercept 25 group had achieved a "good" response and an additional 44% a "moderate" response, compared with 3% and 27%, respectively, in the methotrexate group. At two months, 18% of the etanercept 25 group had achieved a "good" response and an additional 54% a "moderate" response, compared with 7% and 47%, respectively, in the methotrexate group. At six months, 32% of the etanercept 25 group had achieved a "good" response and an additional 48% a "moderate" response. In comparison, 31% of the methotrexate group had achieved a "good" response and an additional 44% a "moderate" response at six months.
To determine the cumulative response over time, these results were quantified as the area under the curve (AUC) of the improvement in DAS. 19 22 This time integrated improvement was significantly better in the etanercept 25 mg group compared with methotrexate at six months (0.9 v 0.7, respectively, p = 0.002) and at 12 months (1.9 v 1.7, respectively, p = 0.031; fig 2) .
Both etanercept 25 mg and methotrexate were shown to be eVective DMARDs with respect to slowing the rate of radiographic progression. At baseline, the predicted annual rate of progression (baseline Sharp score divided by duration of disease) was 9.1 Sharp units, with no significant diVerences among the treatment groups. At one year, 60% of methotrexate patients had no radiographic progression of erosions compared with 72% of etanercept 25 mg patients (p = 0.007). The rates of progression between methotrexate and etanercept 25 mg were significantly diVerent with respect to change in erosions (p < 0.001) and At one year, the median changes in joint erosion, joint space narrowing, and total Sharp score were zero for both groups. Box plots showing changes in erosions and total Sharp score at one year are shown in figures 3 and 4. The range of increase was smaller in the etanercept 25 mg group than in the methotrexate group. In 90% of patients in the etanercept 25 group, the change in erosion score at 12 months was < 2 points, compared with the methotrexate group where, in 90% of patients, the change in erosion score was < 4 points.
More patients withdrew from the study for adverse events in the methotrexate group (11%) than in either etanercept group (6% in the 10 mg and 5% in the 25 mg group). The safety profile of etanercept in this study was similar to that observed in earlier studies. Etanercept was well tolerated and the most commonly reported events in patients receiving etanercept were mild to moderate injection site reactions that did not complicate treatment. Adverse events that occurred at a higher rate in patients receiving methotrexate compared with those receiving etanercept included nausea, rash, mouth ulcers, alopecia, vomiting, and epistaxis. Pneumonitis, seen only in the methotrexate group, developed in three patients. The frequency of any infection was higher in the methotrexate group than the etanercept 25 mg group (p < 0.01), but the rates of infections requiring intravenous antibiotics or hospitalisation were comparable in all three treatment arms.
In summary, etanercept provided rapid and eVective improvement in measures of disease activity in patients with active, early RA and was significantly more eVective than methotrexate in reducing the rate of joint erosions. Etanercept was generally well tolerated and, when compared with methotrexate in this population, was associated with fewer adverse events and withdrawals.
ETANERCEPT IN PSORIATIC ARTHRITIS
The eYcacy of etanercept was also studied in a placebo controlled, double blind study of 60 patients with severe psoriatic arthritis (PsA) who were treated with either etanercept 25 mg or placebo subcutaneously twice weekly for 12 weeks. 23 The end points of the trial were improvement in the PsA response criteria (PsARC) as well as the ACR20 response. The eVect of etanercept on dermatological response was analysed in a subset of patients who had > 3% of total body involvement of their psoriasis by assessing target lesions and by using the Psoriasis Area and Severity Index (PASI), a composite measure based on scale, erythema, and induration of psoriasis lesions.
Patients treated with etanercept had significant improvement in disease activity compared with those given placebo. At 12 weeks, 87% of patients treated with etanercept met the PsARC criteria compared with 23% of patients treated with placebo (p < 0.001). Seventy three per cent of etanercept treated patients achieved an ACR 20 response compared with 13% of placebo treated patients (p < 0.001). Some patients treated with etanercept had a 100% improvement in disease activity, including four with no tender joints, seven with no swollen joints, 11 with no morning stiVness, and 11 with a HAQ zero disability score. Of the 38 patients evaluable for psoriasis, patients receiving etanercept experienced a median improvement in the PASI score of 46% compared with 9% in the placebo group (p = 0.003). No deaths, serious adverse events, or serious infections occurred in either treatment arm.
FURTHER INDICATIONS FOR ETANERCEPT
TNF is an important inflammatory disease mediator in a wide spectrum of articular diseases, including RA, JRA, and PsA. Etanercept is an eVective inhibitor of TNF, has been shown to provide rapid and sustained improvement in these diseases, and is an important new treatment option for patients with these conditions. Etanercept is currently being studied in other disorders in which TNF seems to play an important pathogenic part, including chronic heart failure, sarcoidosis, ankylosing spondylitis, and Wegener's granulomatosis. 
